Involvement of PI3K/Akt pathway in prostate cancer--potential strategies for developing targeted therapies.
about
Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathwayAkt inhibitors: mechanism of action and implications for anticancer therapeutics.Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in miceLoss of the SSeCKS/Gravin/AKAP12 gene results in prostatic hyperplasiaMammalian target of rapamycin complex 1 and cyclooxygenase 2 pathways cooperatively exacerbate endometrial cancer.Murine prostate cancer inhibition by dietary phytochemicals--curcumin and phenyethylisothiocyanateAKT pathway in neuroblastoma and its therapeutic implication.Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy.Overexpression of long non-coding RNA LOC400891 promotes tumor progression and poor prognosis in prostate cancer.The role of Wnt signaling pathway in carcinogenesis and implications for anticancer therapeutics.Regenerating islet-derived family member, 4 modulates multiple receptor tyrosine kinases and mediators of drug resistance in cancer.The transcriptional activation of the cyclooxygenase-2 gene in zymosan-activated macrophages is dependent on NF-kappa B, C/EBP, AP-1, and CRE sites.Upregulation of cyclooxygenase-2 by 4-nonylphenol is mediated through the cyclic amp response element activation pathway.Risk assessment of tetrabromobisphenol A on cyclooxygenase-2 expression via MAP kinase/NF-kappaB/AP-1 signaling pathways in murine macrophages.Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients.Exogenous SPARC suppresses proliferation and migration of prostate cancer by interacting with integrin β1.
P2860
Q28382812-C72F9BF6-A5CB-4982-B917-CD4B9B3029CDQ33641026-32EB4235-F220-4EEA-891B-E3092AC08646Q33667276-07F3FEF3-C9DD-4C3F-9609-D8D2DF71FB43Q33730212-962502EB-FCE1-4E84-83A2-AA1212C24F10Q34299944-4317679B-6611-466F-8D0A-AEAFBA326E84Q36301754-C67252E5-6AB6-4547-A47D-A645911AA815Q37159523-322DD59B-7B7C-4F28-8E21-C38F1609820FQ38180344-A53E72E0-B829-4DD2-A927-045F90A72F0BQ38800573-2C9864E5-0C81-4363-AC97-06FCF988DF75Q39194411-4C08F4D6-F8EF-4BF3-933B-4129A9F82897Q39568944-243BC367-FA84-4D3B-9CD3-CE484F908B45Q39628265-F5F6D9D4-AC67-4F5D-9D10-26BD559A6C68Q39643020-C97650C4-48C4-4236-BD02-407296FB772DQ39751648-44ECF905-4517-43D4-848C-B4DDB128D9EEQ40001031-2F8F75BB-81F6-4F15-BC3C-B7CEF67A0023Q44504681-85E7FCEE-A46B-40E3-90CF-2C1734404A6D
P2860
Involvement of PI3K/Akt pathway in prostate cancer--potential strategies for developing targeted therapies.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Involvement of PI3K/Akt pathwa ...... developing targeted therapies.
@ast
Involvement of PI3K/Akt pathwa ...... developing targeted therapies.
@en
type
label
Involvement of PI3K/Akt pathwa ...... developing targeted therapies.
@ast
Involvement of PI3K/Akt pathwa ...... developing targeted therapies.
@en
prefLabel
Involvement of PI3K/Akt pathwa ...... developing targeted therapies.
@ast
Involvement of PI3K/Akt pathwa ...... developing targeted therapies.
@en
P1476
Involvement of PI3K/Akt pathwa ...... developing targeted therapies.
@en
P2093
Jean-Pierre Hénichart
Nicole Pommery
P304
P356
10.2174/138955705774933356
P577
2005-12-01T00:00:00Z